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Drug-target binding kinetics are suggested to be important parameters for the prediction of in vivo 
drug-efficacy. For G protein-coupled receptors (GPCRs), the binding kinetics of ligands are typically 
determined using association binding experiments in competition with radiolabelled probes, followed 
by analysis with the widely used competitive binding kinetics theory developed by Motulsky and 
Mahan. Despite this, the influence of the radioligand binding kinetics on the kinetic parameters 
derived for the ligands tested is often overlooked. to address this, binding rate constants for a series of 
histamine H1 receptor (H1R) antagonists were determined using radioligands with either slow (low koff) 
or fast (high koff) dissociation characteristics. A correlation was observed between the probe-specific 
datasets for the kinetic binding affinities, association rate constants and dissociation rate constants. 
However, the magnitude and accuracy of the binding rate constant-values was highly dependent on 
the used radioligand probe. Further analysis using recently developed fluorescent binding methods 
corroborates the finding that the Motulsky-Mahan methodology is limited by the employed assay 
conditions. The presented data suggest that kinetic parameters of GPCR ligands depend largely on 
the characteristics of the probe used and results should therefore be viewed within the experimental 
context and limitations of the applied methodology.
The pharmacodynamics of a drug are often related to the half-maximal modulation of target function (IC50, 
EC50), which typically depends on the concentration required to obtain half-maximal target binding (Ki, Kd). 
However, it is increasingly debated whether these pharmacological parameters provides sufficient information 
to predict the in vivo effectiveness of a ligand1–4. Drug-target binding kinetics have therefore received increased 
interest in the last decade, and the drug-target residence time has been linked to the in vivo efficacy of a number of 
important target classes, including the large family of membrane-bound G protein-coupled receptors (GPCRs)3,5–
9. Radioligand binding is routinely used to determine ligand binding affinity and kinetics to GPCR targets10–18. 
To determine the binding kinetics of unlabeled ligands, the competitive effect on the association binding of a 
GPCR radioligand is analyzed using the theoretical model derived by Motulsky and Mahan19. Despite the wide 
use of this methodology in the GPCR-field, it is not known to which extent the calculated binding rate constants 
of unlabeled ligands depend on the binding kinetics of the radiolabeled probe used.
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The histamine H1 receptor (H1R) is a prototypical Family A GPCR which is therapeutically targeted by several 
2nd generation antagonists in the treatment of allergic conditions such as allergic rhinitis and urticaria20. The ther-
apeutic success of the 2nd generation H1R antagonists is generally attributed to their reduced brain penetration 
compared to 1st generation H1R antagonists, which results in a decrease of on-target side effects such as sedation. 
Interestingly, the binding kinetics of several H1R antagonists have been investigated using the Motulsky-Mahan 
methodology13,21–24 and were found to have a long residence time at the H1R25. In one study the prolonged resi-
dence time of levocetirizine was linked to the presence of a carboxylic acid group, which is a frequently occurring 
chemical moiety for 2nd generation antihistamines13.
The success of the H1R as a drug target has resulted in a rich repertoire of antagonists that can bind the 
receptor, including different radiolabeled versions of commonly studied compounds20,21,25–27. Several radioligands 
([3H]mepyramine, [3H]levocetirizine and [3H]olopatadine) have previously been characterized for their kinetic 
binding profile at the H1R. Interestingly, [3H]mepyramine and [3H]levocetirizine show similar binding affinities 
at the H1R, but markedly different binding kinetics21. Recently, methodologies which utilize fluorescent ligands 
in place of radioligands have been introduced to characterize the binding kinetics of GPCR ligands and these 
newer methods have advantages over radioligand binding in terms of throughput and kinetic resolution28. Both 
bioluminescence (BRET29) and time-resolved (HTRF30) resonance energy transfer techniques have been applied 
to study binding kinetics at the H1R.
Due to the wide range of radioactive and fluorescently labelled ligands available for H1R, we used this GPCR 
as a model system to investigate if the measured binding rate constants of unlabeled ligands are influenced by the 
binding kinetics of the employed labelled probe. To this end, [3H]mepyramine and [3H]levocetirizine were used 
to characterize the binding kinetics of a set of unlabeled H1R ligands by the Motulsky-Mahan methodology. This 
was followed by the determination of the binding kinetics of H1R ligands via competitive association binding 
using two different non-radioactive H1R binding assays (BRET-based29 or HTRF based30 approaches). The kon and 
Ki values, obtained from kinetic and steady-state experiments, respectively, were correlated between the various 
datasets employing either fluorescent ligands or radioligands as probes. However, it was found that koff-values are 
in part dependent on the used assay methodology. Therefore, both probe-dependent and assay-dependent factors 
are important contributors to the accurate determination of binding kinetics of unlabeled ligands.
Methods
Materials. The radioligand [3H]mepyramine (20 Ci/mmol) was purchased from Perkin Elmer (Waltham, 
MA, USA). The mepyramine based fluorescent HTRF ligand (Gmep) was purchased from Cisbio (Codolet, 
France). Other employed, commercially available ligands were: triprolidine hydrochloride monohydrate (Tocris 
Bioscience, Bristol, United Kingdom), doxepin hydrochloride (Tocris Bioscience, E/Z mixture with a ~85:15 
ratio), Olopatadine hydrochloride (BOC Sciences, Shirley, NY, USA), acrivastine (BOC Sciences), levocetirizine 
dihydrochloride (Biotrend, Cologne, Germany), S-cetirizine dihydrochloride (TLC PharmaChem, Mississauga, 
Canada), Mepyramine maleate (Research Biochemicals International, Natick, MA, USA), R-fexofenadine 
(Sepracor Inc., Marlborough, MA, USA), S-fexofenadine (Sepracor Inc.), desloratadine (HaiHang Industry, 
Jinan City, China), Terfenadine (MP biomedicals, Santa Ana, CA, USA). VUF14454, VUF14544, VUF14506, 
VUF14493 and mianserin were synthesized at the Vrije Universiteit Amsterdam and were fully characterized 
with respect to purity and identity22,23. [3H]levocetirizine (25.9 Ci/mmol) was synthesized at AstraZeneca and 
was fully characterized with respect to purity and identity. AV082 (mepyramine-ala-ala-BY630) was synthesized 
at the University of Nottingham as described previously29. All other chemicals and reagents were obtained from 
Sigma Aldrich and Fisher, unless specified otherwise in the text.
synthesis of [3H]olopatadine. General. The synthesis of [3H]olopatadine is schematically depicted 
in Fig. 1. Column chromatography was carried out using pre-packed silica gel cartridges (SiliCycle, Quebec, 
Canada) on an Isco Companion (Teledyne Isco, NE, USA). 1H NMR spectra were recorded on a Bruker (600 MHz 
or 400 MHz) using the stated solvent. Chemical shifts (δ) in ppm are quoted relative to CDCl3 (δ 7.26 ppm) and 
DMSO-d6 (δ 2.50 ppm). Liquid chromatography-mass spectrometry (LC-MS) data was collected using a Waters 
Figure 1. Synthesis of [3H]olopatadine. Key: (a) 4-toluenesulfonic acid, EtOH, reflux, 2 h, 89%; (b) (i), 
1-chloroethyl chloroformate, DCE, reflux, 4 h; (ii) MeOH, reflux, 2 h, 10% over two steps; (c) [3H]methyl 
nosylate, DMF, 50 °C, 1 h; (d) NaOH, EtOH/H2O, r.t., 2 h.
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Alliance LC (Waters Corporation, MA, USA) with Waters ZQ mass detector. Analytical HPLC data was recorded 
using Agilent 1200 HPLC system with a β-Ram Flow Scintillation Analyser, using the following conditions: 
Waters Sunfire C18, 3.5 µm, 4.6 × 100 mm column at 40 °C, eluting with 5% acetonitrile/water +0.1% TFA to 
95% acetonitrile/water +0.1% TFA over a 32 minute gradient. Specific activities were determined gravimetrically 
with a Packard TriCarb 2100CA Liquid Scintillation Analyser (Packard Instrument Company Inc., IL, USA) 
using Ultima GoldTM cocktail. Reactions with tritium gas were carried out on a steel manifold obtained from RC 
Tritec AG (Teufen, Switzerland). Specific activity was calculated by comparison of the ratio of tritium/hydrogen 
or carbon-14/carbon-12 for the tracer against the unlabelled reference. [3H]Methyl nosylate was obtained from 
Quotient Bioresearch as a solution in toluene at 3150 GBq mmol−1. Tritium gas was supplied absorbed onto a 
depleted uranium bed by RC Tritec AG (Teufen, Switzerland).
Ethyl (Z)-2-(11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetate. (Z)-2-(11-
(3-(dimethylamino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetic acid hydrochloride (150 mg, 
0.40 mmol), ethanol (3 mL, 0.40 mmol) and 4-toluenesulfonic acid (23 mg, 0.12 mmol) were stirred at reflux under 
Dean-Stark conditions for 2 h. Triethylamine (73 µL, 0.52 mmol) was added and the mixture evaporated under 
reduced pressure, the residue was partitioned between water (5 mL) and ethyl acetate (15 mL). The organic phase 
was washed with NaHCO3 (satd. aq, 5 mL), brine (5 mL), dried (MgSO4), filtered and evaporated to give ethyl 
(Z)-2-(11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetate (131 mg, 0.358 mmol, 
89%) as a colourless oil. LCMS (ESI) m/z 366 [M + H]+.
Ethyl (Z)-2-(11-(3-(methylamino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetate. 1-Chloroethyl 
chloroformate (38.2 µl, 0.35 mmol) was added to a stirred solution of ethyl (Z)-2-(11-(3-(dimethylamino)propyl
idene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetate (128 mg, 0.35 mmol) in 1,2-dichloroethane (3500 µL) and 
the mixture heated to reflux. After 2 h additional 1-chloroethyl chloroformate (38.2 µL, 0.35 mmol) was added, 
and after a further 2 h the solvent was evaporated under reduced pressure. Methanol (3 mL) was added and the 
mixture heated to reflux for 2 h. The mixture was purified by preparative HPLC (Waters XBridge Prep C18 OBD 
column, 5 µ silica, 19 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 0.1% 
TFA) and MeCN as eluents. Fractions containing the desired compound were combined, concentrated under 
vacuum, adjusted to pH 9 with NaHCO3, extracted with DCM (2 × 20 mL), then further purified by flash silica 
chromatography, elution gradient 0 to 6% NH3-MeOH (7 M) in DCM to afford ethyl (Z)-2-(11-(3-(methylamino)
propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetate (12 mg, 0.034 mmol, 10%) as a colourless gum. 
LCMS (ESI) m/z 352 [M + H]+. 1H NMR (600 MHz, DMSO-d6) 1.17 (t, J = 7.0 Hz, 3H), 2.24 (s, 3H), 2.45–2.5 
(m, 2H), 2.62 (t, J = 6.8 Hz, 2H), 3.57 (s, 2H), 4.06 (q, J = 7.0 Hz, 2H), 5.16 (s, 2H), 5.70 (t, J = 7.2 Hz, 1H), 6.76 (d, 
J = 8.3 Hz, 1H), 7.05 (dd, J = 2.3, 8.3 Hz, 1H), 7.08 (d, J = 2.3 Hz, 1H), 7.26 (d, J = 7.6 Hz, 1H), 7.28–7.32 (m, 1H), 
7.35 (t, J = 7.4 Hz, 2H).
Ethyl (Z)-2-(11-(3-(([3H]methyl)(methyl)amino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetate. [3H]
Methyl nosylate in toluene (2.5 mL, 1080 MBq) was concentrated under a stream of nitrogen. To this was added 
a solution of ethyl (Z)-2-(11-(3-(methylamino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetate 
(0.86 mg, 2.4 µmol) in DMF (0.5 mL) and the mixture stirred at 50 °C for 1 h. After lyophilisation, a solution of 
di-tert-butyldicarbonate (1.1 mg, 4.9 µmol) in DCM (1 mL) was added to the residue and the mixture stirred for 
1 h then purified by silica chromatography eluting with 0 to 6% NH3-MeOH (7 M) in DCM. Fractions containing 
product were evaporated and dissolved in ethanol (1 ml) to give ethyl (Z)-2-(11-(3-(([3H]methyl)(methyl)amino)
propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetate solution. LCMS (ESI) m/z 372 [M + H]+.
(Z)-2-(11-(3-(([3H]methyl)(methyl)amino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetic acid ([3H]
Olopatadine). Sodium hydroxide (2 M aq, 200 µL) was added to the ethanol solution (1 mL) of ethyl (Z)-2-
(11-(3-(([3H]methyl)(methyl)amino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetate (0.11 mg, 0.28 
µmol) and the mixture stirred for 2 h. The ethanol was evaporated and water (1 mL) was added. The pH was 
adjusted to 9 by addition of HCl (2 M) and the mixture concentrated then purified on a Waters Oasis HLB car-
tridge, washing with water (5 mL), drying under a flow of nitrogen and then eluting with acetonitrile (5 mL). 
Purification by preparative HPLC (Waters XBridge C18 column, 4.6 × 150 mm) using decreasingly polar mix-
tures of water (containing 0.1% NH3) and MeCN as eluents afforded [3H]olopatadine (107 MBq) which was 
dissolved in ethanol (2 mL) for storage as a colourless solution. Radiochemical purity >98%. LCMS (ESI) m/z 344 
[M + H]+. 3H NMR (640 MHz, DMSO-d6) 2.00 (s). Specific activity by mass spectrometry: 2920 GBq mmol−1.
Cell culture. Human embryonic kidney cells transformed with large T antigen (HEK293T) and stably expressing 
Nluc-H1 were generated as described elsewhere29, as is the transient transfection of these HEK293T cells with 
the N-terminally HA-tagged H1R31. Both native and transfected HEK293T cells were maintained in Dulbecco’s 
Modified Eagles medium supplemented with 10% fetal calf serum at 37 °C, 5% CO2. Cell pellets of transiently 
transfected HEK293T cells were prepared and stored at −20 °C until used in radioligand binding experiments, 
as previously described31. Frozen aliquots of TagLite® cells expressing the Tb-labeled SNAP-H1R were acquired 
from Cisbio.
Radioligand binding assays. Radioligand binding experiments were performed as described before with 
minor alterations as summarized below31. Frozen cell pellets of HEK293T cells transiently expressing the H1R 
were thawed, resuspended in radioligand binding buffer (50 mM Na2HPO4 and 50 mM KH2PO4, pH 7.4) and 
homogenized with a Branson sonifier 250 (Branson Ultrasonics, Danbury, CT, USA). Homogenates (0.5–3 mg/
well) were then incubated with the respective ligands at 25 °C under gentle agitation. For equilibrium saturation 
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binding, increasing concentrations [3H]mepyramine or [3H]levocetirizine were incubated for 4 h in the absence 
or presence of mianserin (10 µM). Mianserin has a pKi at the H1R of 9.4 ± 0.1 (not shown) and the used concen-
tration should therefore prevent any specific binding of the radioligands. For equilibrium competition binding, 
[3H]mepyramine (3 nM) was used in the presence of increasing concentrations unlabeled ligands. In radioli-
gand association binding experiments, four concentrations [3H]mepyramine (0.2–10 nM), [3H]levocetirizine 
(1–60 nM) or [3H]olopatadine (9–19 nM) were used. Moreover, radioligand association binding was performed 
at 37 °C as well as 25 °C. For competitive association binding experiments 1–100x Ki concentrations of the respec-
tive unlabeled ligand were co-incubated with a single concentration of radioligand ranging between 1.5–12 nM 
for [3H]mepyramine or 5–15 nM for [3H]levocetirizine. Kinetic ligand binding was performed for the depicted 
incubation times.
For dissociation experiments a single concentration of [3H]mepyramine (3–13 nM), [3H]levocetirizine 
(2–50 nM) or [3H]olopatadine (10–15 nM) was pre-incubated with cell homogenate for 2 h (0.5–3 mg/well), after 
which a saturating concentration mianserin (10 µM) was added for various incubation times (triplicate binding 
reactions per time point). Non-specific binding was determined by the presence of mianserin (10 µM) during the 
pre-incubation step. Dissociation experiments were performed at both 37 °C and 25 °C.
Binding reactions were terminated using a cell harvester (Perkin Elmer) by rapid filtration and wash steps 
over PEI-coated GF/C filter plates. Filter bound radioligand was then quantified by scintillation counting using 
Microscint-O and a Wallac Microbeta counter (Perkin Elmer).
HtRF binding assays. HTRF based binding assays were performed as described before30 with minor 
changes as summarized below. The mepyramine based fluorescent ligand (Gmep, Cisbio; time-resolved fluo-
rescence resonance energy transfer (TR-FRET) acceptor) and unlabeled ligands were predispensed in 384-well 
plates. Binding reactions were started upon addition of TagLite® cells expressing the Tb-labeled SNAP-H1R 
(Cisbio) (1:8 predilution and 1:2.5 dilution in well; TR-FRET donor). TR-FRET signals arising from Gmep bind-
ing were measured at room temperature with an excitation wavelength of 337 nm and emission wavelengths of 
490 ± 10 and 520 ± 10 nm, using a PHERAstar FS plate reader (BMG Labtech) with syringes for sample injection. 
The ratio values (520 nm/490 nm * 10000) were calculated as defined in the instrument software.
The steady-state affinity of the probe was determined by saturation binding experiments. Increasing con-
centrations of Gmep (2 fold serial dilution; 3.66 × 10−10 M–3 × 10−6 M; and 0 M) were incubated for 2.5 h in the 
absence and presence of doxepin hydrochloride (1 µM). Kinetic rate constants of Gmep binding were obtained 
with “association then dissociation” experiments32. Briefly, H1R expressing cells were added to increasing con-
centrations of Gmep in the absence and presence of doxepin hydrochloride (1 µM) and association was meas-
ured for 25.6 min with kinetic intervals of 26 s. Dissociation of Gmep was immediately initiated by addition of 
doxepin hydrochloride (1.1 µM) and detected for a further 40 min with kinetic intervals of 100 s. Competitive 
binding experiments were performed to quantify the affinities and kinetic rate constants of ligand binding: Gmep 
(100 nM) was co-incubated with increasing concentrations unlabeled ligands for 3 h as an endpoint measurement 
(11-point 3.5 fold serial dilutions of ligand, and 0 nM) or with a kinetic interval of 60 s for competitive association 
experiments (kPCA; 4-point 10 fold serial dilutions of ligand).
NanoBRet binding assays. For NanoBRET assays, HEK293Tcells stably expressing Nluc-H1 were seeded 
24 h before experimentation in white Thermo Scientific 96-well microplates in normal growth medium. For sat-
uration and competition experiments, the medium was removed and replaced with HEPES-buffered saline solu-
tion (HBSS; 25 mM HEPES, 10 mM glucose, 146 mM NaCl, 5 mM KCl, 1 mM MgSO4, 2 mM sodium pyruvate, 
1.3 mM CaCl2) with the required concentration of AV082 and competing ligand. Cells were then incubated for 
1 h at 37 °C (no CO2). The Nluc substrate furimazine (Promega) was then added to each well at a final concentra-
tion of 10 µM and allowed to equilibrate for 5 min prior to measurement of fluorescence and luminescence. For 
association kinetic and competitive association kinetic experiments, medium was replaced by HBSS containing 
furimazine (10 µM) and incubated at room temperature in the dark for 15 min to allow the luminescence signal to 
reach equilibrium. For association kinetic experiments, the required concentration of AV082 in the presence and 
absence of doxepin (10 µM) was then added simultaneously. Immediately after, all wells of the microplate were 
read once per minute for 60 min. For competitive association experiments, AV082 (10 nM) was added simulta-
neously with the required concentration of unlabeled ligand or doxepin (10 µM) and read once per minute for 
60 min. For all experiments fluorescence and luminescence was read sequentially using the PHERAstar FS plate 
reader (BMG Labtech) at room temperature. Filtered light emissions were measured at 460 nm (80-nm bandpass) 
and at >610 nm (longpass) and the raw BRET ratio was calculated by dividing the >610-nm emission by the 
460-nm emission.
Data analysis. Analysis of saturation binding experiments, competition binding experiments and associa-
tion binding experiments are fully described elsewhere29–31. The kinetic experiments were analyzed by GraphPad 
Prism (GraphPad Software, Inc., La Jolla, CA, USA) using non-linear regression of the data to pharmacological 
models that assume a one-step binding of the ligand to the receptor.
Competitive association – Motulsky-Mahan model
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The baseline signal was subtracted from the total signal obtained in competitive association experiments. In 
the case of radioligand binding experiments and NanoBRET experiments equation (1) was employed to fit the 
data. In the case of HTRF experiments the adapted equation (2) is used to account for the observed signal drift 
(using kdrift as a fitting constant). RL* is the baseline corrected signal that corresponds to the level of receptor 
binding by the labeled ligands. Bmax is the theoretical RL* in the case that all receptors would be occupied by 
the labeled ligand. [L*] and [I] stand for the concentrations labeled ligand and unlabeled ligand, respectively. 
Association rate constants are denoted by k1 or k3 and the dissociation rate constants by k2 or k4 for labeled ligand 
or cold ligand respectively. For the kinetics of competitive binding model, binding rate constants of the labeled 
ligands are required to fit the binding rate constants of the unlabeled ligand. The relative error was calculated for 
k3 and k4 values by dividing the reported error of the non-linear regression (SE) by the fitted mean value.
Dissociation experiments. Non-specific binding was subtracted from the total bound radioligand and the result-
ing specific radioligand binding over time was analyzed with a one-phase dissociation model (Graphpad prism: 
‘Dissociation – One phase exponential decay’). When the radioligand was not fully dissociated within the time-
span of the experiment, the final steady-state radioligand binding was constrained to baseline during analysis.
Results
Characterization of radioligand probes. To explore how the binding kinetics of a radioligand affects the 
Motulsky-Mahan analysis of radioligand association in competition with unlabeled GPCR ligands, three different 
radioligands and two fluorescence-based probes for the H1R were investigated in this study. In addition to the 
widely used and commercially available [3H]mepyramine (fast off rate), radiolabeled versions of the 2nd genera-
tion antihistamine radioligands olopatadine and levocetirizine (slow off rate)21,33 were synthesized as described in 
the method section and structures are depicted in Fig. 2. Equilibrium binding of increasing concentrations of [3H]
mepyramine (Fig. 3a), [3H]levocetirizine (Fig. 3b) or [3H]olopatadine (Fig. 3c) to H1R-expressing HEK293T cell 
homogenates, revealed that all radioligands saturably bind to the H1R with high affinities, resulting in pKd values 
of 8.6 ± 0.1, 8.1 ± 0.1 and 8.7 ± 0.1, respectively (Table 1). Moreover, saturation binding experiments revealed 
similar Bmax values (25–31 pmol receptor per mg protein) for all three radioligands, indicating that these three 
radioligands interact with the same H1R population. To determine the binding rate constants of the radioligands 
at the H1R, four different concentrations of either [3H]mepyramine (Fig. 3d), [3H]levocetirizine (Fig. 3e) or [3H]
olopatadine (Fig. 3f) were incubated with cell homogenate for increasing incubation times and the data was fitted 
using a one-step binding model. The rate constants (kon and koff) of [3H]levocetirizine binding to the H1R are 
30- to 100-fold lower than the binding rate constants of [3H]mepyramine binding (Table 1), as was previously 
described21. The binding rate constants of the 2nd generation antihistamines [3H]levocetirizine and [3H]olopat-
adine were comparable (<2 fold differences). Moreover, equilibrium dissociation constants calculated from the 
Figure 2. Structures of the used probes. T indicates a tritium atom.
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binding rate constants (pKd,kin = koff/kon) were in good agreement with equilibrium dissociation constants deter-
mined by saturation binding experiments (pKd) (Table 1).
The koff values of the radioligand probes were verified by radioligand displacement experiments, in which 
pre-bound radioligand is forced to dissociate by a high concentration of the unlabeled competitor mianserin 
(Supplementary Fig. 1). The koff values of [3H]mepyramine and [3H]levocetirizine deviated less than 1.5-fold 
between the association and dissociation experiments (Supplementary Table 2). However, there was very lit-
tle dissociation of [3H]olopatadine within the 6 hour time frame measured (Supplementary Fig. 1c). To accel-
erate the association and dissociation of the radioligands and, thereby obtain a more robust quantification 
of the binding kinetics for the three radioligands, experiments were also performed at 37 °C (Supplementary 
Fig. 1)21. As expected, both the kon and the koff values of [3H]mepyramine and [3H]levocetirizine increased by 
3–10 fold (Supplementary Table 2). However, even at 37 °C there was still limited dissociation of [3H]olopata-
dine within the 6 h time span. Interestingly, at 37 °C the association of [3H]olopatadine was not described well 
by a mono-exponential increase in binding as expected for a one-step binding mechanism. Consequently, [3H]
olopatadine was therefore excluded as probe, as the Motulsky-Mahan model that is used to describe competitive 
association ligand binding is based a one-step binding mechanism.
Quantifying the binding characteristics of unlabeled H1R antagonist. A chemically diverse set 
of unlabeled H1R ligands (structures are depicted in Supplementary Fig. 2), including reference molecules with 
known differences in their H1R binding kinetics, was selected for characterization of their H1R binding kinetics 
using either [3H]mepyramine or [3H]levocetirizine13,23,31. To guide the design of competitive association experi-
ments, binding affinities (Ki) of the unlabeled ligands were first determined by equilibrium competition binding. 
Figure 3. Binding of [3H]mepyramine, [3H]levocetirizine and [3H]olopatadine to the H1R. Increasing 
concentrations of [3H]mepyramine (a), [3H]levocetirizine (b) or [3H]olopatadine (c) were incubated with 
H1R-expressing cell homogenates for 4 h at 25 °C. Indicated concentrations of [3H]mepyramine (d), [3H]
levocetirizine (e) or [3H]olopatadine (f) were incubated with cell homogenate for several incubation times 
at 25 °C. Representative graphs are shown of ≥3 experiments and the depicted data points represent the 
mean ± SEM of triplicate values (a–c) or depict individual measurements with duplicate values per time point 
(d–f). Extracted binding constants and statistical information are shown in Table 1 and Supplementary Table 2.
[3H]mepyramine [3H]levocetirizine [3H]olopatadine Gmepa AV082b
pKd 8.6 ± 0.1 8.1 ± 0.1 8.7 ± 0.1 7.3, 7.3 8.1 ± 0.1
pKd,kin (koff/kon) 8.7 ± 0.0 8.7 ± 0.2 9.3 ± 0.2 7.0, 6.8 8.3 ± 0.0
kon 106 min−1 M−1 112 ± 5 1.1 ± 0.1 2.0 ± 0.1 1.58, 0.86 46 ± 6
koff min−1 0.22 ± 0.01 0.0023 ± 0.0006 0.0016 ± 0.0003 0.17, 0.13 0.21 ± 0.03
RT min 4.7 ± 0.3 600 ± 200 600 ± 100 5.9, 7.9 5.0 ± 0.8
Bmax (pmol/mg) 26 ± 4 31 ± 4 25 ± 4 NA NA
Table 1. H1R binding parameters of radioligand and fluorescent probes at 25 °C. Values represent the 
mean ± SEM of ≥3 experiments (number of experiments are reported in Supplementary Table 1). NA, not 
applicable. aIndividual values are shown (2 experiments), which are similar to value reported in Schiele et al.30; 
bAs reported in Stoddart et al.29.
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Cell homogenates were therefore co-incubated with [3H]mepyramine and increasing concentrations of the unla-
beled ligands (Supplementary Fig. 3). Binding affinities (Ki) for H1R were calculated from the determined IC50 
values using the Cheng-Prusoff equation34 and are depicted in Supplementary Table 3.
The binding rate constants of the unlabeled ligands at the H1R were determined by competitive association 
binding experiments, in which H1R binding of the radioligand probes is quantified over time in the absence or 
presence of unlabeled ligands at three different concentrations. Concentrations of unlabeled ligand were varied 
ten-fold between the lowest and highest used concentration which was within an equipotent range of 1–100 times 
the respective Ki of the ligands at the H1R. From the resulting radioligand association binding curves, the binding 
rate constants of unlabeled ligands can be determined by Motulsky-Mahan analysis (Fig. 4, Table 2)19. As each 
time point requires a new binding reaction, the kinetic resolution for quantifying radioligand binding is limited 
Figure 4. Association binding of [3H]mepyramine and [3H]levocetirizine in the presence of competing 
unlabeled ligands at the H1R at 25 °C. The kinetic binding of [3H]mepyramine to H1R-expressing cell 
homogenates was measured with various concentrations of either mepyramine (a) doxepin (b) or levocetirizine 
(c). Similarly, the kinetic binding of [3H]levocetirizine to H1R-expressing cell homogenates was measured 
in competition with various concentrations of either mepyramine (d) doxepin (e) or levocetirizine (f). 
Representative graphs are shown of ≥3 experiments and each condition was measured in duplicate. Extracted 
binding constants and statistical information are shown in Table 2 and Supplementary Table 2.
[3H]mepyramine [3H]levocetirizine
pKd,kina konb koffb RTb pKd,kina kon koff RTb
106 min−1 M−1 min−1 min 106 min−1 M−1 min−1 min
olopatadine 8.5 ± 0.0 1.8 ± 0.1 0.0061 ± 0.0004 170 ± 10 9.3 ± 0.3 1.6 ± 0.5 0.0007 ± 0.0002 1600 ± 400
levocetirizine 8.2 ± 0.1 1.2 ± 0.2 0.008 ± 0.001 140 ± 20 8.5 ± 0.0 1.4 ± 0.1 0.0049 ± 0.0008 230 ± 30
desloratadine 9.5 ± 0.0 30 ± 10 0.008 ± 0.003 160 ± 50 9.3 ± 0.1 9 ± 2 0.0044 ± 0.0006 240 ± 30
(S)fexofenadine 7.4 ± 0.1 0.23 ± 0.03 0.011 ± 0.003 110 ± 30 7.9 ± 0.0 0.19 ± 0.01 0.0022 ± 0.0002 450 ± 40
(R)fexofenadine 7.3 ± 0.1 0.24 ± 0.03 0.013 ± 0.003 90 ± 20 7.7 ± 0.1 0.18 ± 0.01 0.0040 ± 0.0006 260 ± 40
doxepin 9.1 ± 0.1 70 ± 10 0.06 ± 0.02 22 ± 7 9.7 ± 0.1 80 ± 30 0.014 ± 0.003 80 ± 20
(S)cetirizine 6.4 ± 0.1 0.21 ± 0.01 0.09 ± 0.01 11 ± 1 6.8 ± 0.1 0.4 ± 0.2 0.05 ± 0.02 27 ± 8
triprolidine 8.1 ± 0.1 36 ± 5 0.30 ± 0.03 3.5 ± 0.4 8.7 ± 0.0 30 ± 10 0.05 ± 0.02 30 ± 9
mepyramine 8.8 ± 0.1 200 ± 50 0.28 ± 0.05 3.9 ± 0.6 8.8 ± 0.1 40 ± 10 0.07 ± 0.02 20 ± 8
VUF14454 8.6 ± 0.1 250 ± 90 0.6 ± 0.1 1.8 ± 0.3 8.7 ± 0.0 11 ± 2 0.026 ± 0.005 41 ± 7
VUF14493 8.4 ± 0.1 300 ± 100 0.9 ± 0.2 1.1 ± 0.2 8.6 ± 0.0 80 ± 70 0.2 ± 0.2 20 ± 10
VUF14544 7.8 ± 0.1 100 ± 40 1.3 ± 0.3 0.9 ± 0.2 7.9 ± 0.0 2.4 ± 0.4 0.032 ± 0.004 33 ± 5
Table 2. Binding rate constants and calculated pKd and RT of unlabeled ligands at the H1R. Values represent the 
mean ± SEM of n experiments as reported in Supplementary Table 1. Competitive association experiments were 
performed with [3H]mepyramine or [3H]levocetirizine as the probe, with representative graphs shown for a 
subset unlabeled ligands in Fig. 4. apKd,kin = koff/kon. bValues were reported before except for (S)fexofenadine, (R)
fexofenadine and (S)cetirizine23. cRT = residence time = 1/koff.
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and dependent on the number of parallel incubations. Therefore, incubation times were adjusted for the indi-
vidual radioligands to best capture their kinetic profile. For the rapidly binding radioligand [3H]mepyramine a 
relatively short 80 min incubation time was chosen (Fig. 4a–c), whereas a 360 min incubation time was employed 
for the slowly binding probe [3H]levocetirizine (Fig. 4d–f). The association of the radiolabeled probes to the H1R 
in the presence and absence of three competing unlabeled ligands with (from left to right) fast, intermediate, and 
slow binding kinetics, is depicted in Fig. 4 and covers the diversity in binding kinetics observed within the full 
set of unlabeled ligands. Binding of [3H]mepyramine in the presence of unlabeled mepyramine leads to a grad-
ual increase in radioligand binding until binding equilibrium has been established after approximately 10 min 
(Fig. 4a). In the presence of doxepin and levocetirizine there is first a transient overshoot in the binding of [3H]
mepyramine which results from the relatively slow dissociation (lower koff value) of both unlabeled ligands com-
pared to the rapid binding of [3H]mepyramine (Fig. 4b,c). Conversely, since [3H]levocetirizine binds much slower 
than [3H]mepyramine (Fig. 3d,e), no overshoot pattern is observed for [3H]levocetirizine binding to the H1R in 
the presence of the same three unlabeled ligands (Fig. 4d–f). The selected time points and length of incubation 
depended on the employed radioligand (Fig. 4), which might also affect the resulting binding rate constants in 
competitive association experiments.
Probe dependent differences in binding characteristics. The observed association binding data of 
both radioligands (Fig. 4a–f) agreed well with the fitted non-linear regression lines based on the Motulsky-Mahan 
model from which binding rate constants (kon and koff) of the unlabeled ligands could be calculated (Table 2). 
Thus, two datasets were obtained with the binding rate constants of unlabeled ligands that were determined by 
using either [3H]mepyramine or [3H]levocetirizine as competitive probe. The measured binding rate constants 
correlated well between datasets as is depicted in Fig. 5a (kon values: R2 = 0.80, P < 0.001) and in Fig. 5b (koff 
values: R2 = 0.77, P = 0.002). However, the regression lines (solid lines) deviate from unity (dashed line) and 
some unlabeled ligands showed larger differences in binding kinetics between the two datasets than others. For 
example, more than 10-fold differences in the kon and koff values were observed for VUF14454 and VUF14544 
between both datasets (with the Kd,kin, calculated as the koff/kon, deviating less than 2-fold). The differences in 
the kon values between datasets were largest for ligands with a relatively high koff value (Table 2). Additionally, 
a probe-dependent difference for the range in koff values was observed, with [3H]mepyramine discriminating 
unlabeled ligands over a range with higher koff-values (Fig. 5b, logkoff −2.2 and 0.1) and [3H]levocetirizine dis-
criminating unlabeled ligands over a range with lower koff-values (Fig. 5b, logkoff −3.2 and −0.7). These data 
suggest that the [3H]mepyramine-based assay better distinguishes fast dissociating unlabeled ligands(high koff 
values), whereas the [3H]levocetirizine-based assay better distinguishes slow dissociating unlabeled ligands (low 
koff values). From the determined binding rate constants, the binding affinity (pKd,kin = koff/kon) and the resi-
dence time (RT = 1/koff), a proposed metric to relate binding kinetics to in vivo drug efficacy3,5–9, were calculated 
(Table 2). The pKd,kin values correspond well with the respective pKi values (Fig. 5c), with a good correlation for 
both the [3H]mepyramine-dataset (R2 = 0.93, P < 0.0001) and [3H]levocetirizine-dataset (R2 = 0.87, P < 0.0001). 
Furthermore, the pKd,kin values correlate nicely between the probe specific datasets as well (R2 = 0.87, P < 0.0001, 
data not shown). Since the Kd,kin value is directly derived from the binding rate constants (koff/kon), these corre-
lations highlight the reciprocal changes in kon- and koff values in both binding assays and suggests that the ratio 
between the binding rate constants (e.g., reflected by the steady state level of radioligand binding, Fig. 4) is more 
robustly determined by the Motulsky-Mahan model than the binding rate constants themselves.
To investigate the accuracy of the obtained kon and koff values, the relative errors of the fitted binding rate 
constants were calculated for each individual experiment for both data sets. The relative errors of the kon and the 
koff values were plotted against the corresponding mean koff value for each individual competitive association 
Figure 5. Comparison of the binding properties of unlabeled ligands as measured by using two different 
probes at 25 °C. Binding rate constants of unlabeled ligands were determined in radioligand binding studies. 
A correlation plot is depicted for the logkon (a) and logkoff (b) as determined from competitive association 
experiments using either [3H]mepyramine (x-axis) or [3H]levocetirizine (y-axis) as competitive probe. (c) The 
correlation plot between the affinity calculated from the kinetic binding rate constants (pKd,kin) and the affinity 
from competition binding experiments (pKi) is depicted. Errors represent SEM values. Dashed lines represent a 
perfect correlation respective to the X-axis values and solid lines represent the linear regression lines.
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experiment, as depicted in Fig. 6. It is shown that the relative error on the determined binding rate constants 
depends on the fitted mean koff values of unlabeled ligands at the H1R (Fig. 6). For both binding-rate-constants 
a decrease in accuracy, i.e. an increase in the relative error, is observed for unlabeled ligands with high mean 
koff-values at the H1R (Fig. 6a,b) as is apparent for, e.g., −logkoff values > −1. Additionally, an increase in the rela-
tive error on the koff-values (Fig. 6b), but not on the kon-values (Fig. 6a), is observed for unlabeled ligands with low 
mean koff-values as is apparent for, e.g., −logkoff values < −2. Interestingly, Fig. 6 clearly shows a probe-dependent 
accuracy for the determination of the kon and the koff- values of unlabeled ligands. The kon value for H1R binding 
is generally more accurate when determined in a [3H]mepyramine binding experiment (blue curve, Fig. 6a), 
whereas the koff value is more accurate for the [3H]levocetirizine dataset in the case of unlabeled ligands with a 
logkoff < −2 and less accurate for ligands with a logkoff > −2 (red curve, Fig. 6b).
Cross-comparison between fluorescent-ligand and radioligand binding experiments. Recently, 
promising advances using resonance energy transfer techniques have been made in the use of fluorescent lig-
ands as probes to characterize the binding kinetics of unlabeled ligands to GPCRs such as the H1R29,30. Since the 
binding of a fluorescent ligand can be measured continuously using a HTRF or NanoBRET-based approach, the 
kinetic resolution and throughput of such assays are much higher than conventional radioligand binding kinet-
ics experiments. The availability of these assays for H1R, allows them to be compared to traditional radioligand 
binding assays for measuring the binding kinetics of unlabeled ligands. We initially sought to characterize the 
binding kinetics of the fluorescent probes in both the NanoBRET and HTRF assays. For the NanoBRET binding 
assay a BODIPY630/650-labeled mepyramine analog which emits in the red range (AV082; formally described as 
compound 10 in Stoddart et al.29 and depicted in Fig. 2) is used as fluorescent probe and is used with HEK293T 
cells expressing H1R tagged on the N-terminus with NanoLuc which are grown in a mono-layer. For the HTRF 
binding assay, a commercially available fluorescent analog of mepyramine (structure unknown) which emits 
light in the green range (Gmep) was employed alongside TagLite® cells expressing an N-terminally SNAP-tagged 
H1R and labelled with terbium cryptate. Characterization of both fluorescent probes was as previously described 
(Table 1)29,30. Although the relative large size of the attached fluorophore is likely to affect the binding properties 
of the unlabeled ligand29, the koff value for the binding of mepyramine-analogs AV082 and Gmep to the H1R 
resembled those of [3H]mepyramine (<2-fold difference), albeit with differences in their kon values (2–100 fold) 
(Table 1).
Both non-radioactive assays were used to characterize the H1R binding properties of the set of unlabeled lig-
ands depicted in Supplementary Fig. 2. Equilibrium competition binding experiments were performed to obtain 
pKi values of the unlabeled ligands as described before29,30 (Supplementary Fig. 3, Supplementary Table 3) and lig-
ands were further characterized in kinetic competition association experiments (Fig. 7, Supplementary Table 4). 
For the binding of AV082 measured by NanoBRET, in line with the competitive association experiments using 
[3H]mepyramine (Fig. 7a–c), an overshoot was apparent when co-incubated with doxepin and levocetirizine but 
not with mepyramine. Kinetic binding rate constants were determined by fitting the NanoBRET signal over time 
to the Motulsky-Mahan model.
For the competitive association experiments with Gmep (Fig. 7d–f), a signal drift was observed in the 
absence of unlabeled ligand. To allow robust fitting of the HTRF signal (including the signal drift), an additional 
one-phase decay function was incorporated into the Motulsky-Mahan model, as described before30. Despite the 
Figure 6. Accuracy of the measured binding rate constants depend on the fitted mean koff of unlabeled ligands 
at the H1R at 25 °C. The accuracy in which the Motulsky-Mahan model fitted the kon (a) and koff (b) by non-
linear regression was examined for the different experimental conditions that were employed in this study. To 
compare the accuracy of the fitted mean kon and koff values over a broad range, the relative magnitude of the 
error (SE), as derived from non-linear regression, was calculated for each individual replicate experiment and 
pooled for all ligands. The relative error was calculated by normalizing the SE by the mean (relative error = SE/
mean). Subsequently, the relative error for the kon and koff were plotted against the corresponding mean koff 
determined from the same competitive association curve. Data points derived from competitive association 
experiments that employed [3H]levocetirizine are depicted in red. The arrows depict the koff of the used probes 
with [3H]levocetirizine in red and [3H]mepyramine in blue as reported in Table 1. Dashed lines represent a 
relative error of 1 (mean = SE).
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signal drift, an overshoot in Gmep binding is apparent in competition association experiments with unlabeled 
ligands with slow binding kinetics. After an initial rapid increase of Gmep binding, the HTRF-signal decreases 
much faster when co-incubated with 25 nM or 250 nM levocetirizine than in the absence of any competitor 
(Fig. 7f). In contrast, in the presence of mepyramine (Fig. 7d), the HTRF-signal never decreased faster than was 
observed for Gmep in the absence of unlabeled ligand.
A comparison of the binding constants that were obtained with [3H]mepyramine binding (x-axis) and the 
two fluorescent binding assays (y-axis) are depicted in Fig. 8a–c and Supplementary Table 3. Interestingly, a 
good correlation was observed between assays for the relative binding affinities (pKi) (Fig. 8a; (AV082: R2 = 0.88, 
P < 0.0001; Gmep: R2 = 0.94, P < 0.0001) and logkon values (Fig. 8b; AV082: R2 = 0.84, P < 0.0001; Gmep: 
R2 = 0.92, P < 0.0001). Although, the use of AV082 in probe-displacement experiments resulted additionally 
in a log-unit lower pKi-values compared to values obtained in the orthogonal assays (Fig. 8a). Moreover, the 
Figure 7. Association binding of AV082 and Gmep in the presence of competing unlabeled ligands at the 
H1R at 25 °C. The kinetic binding of AV082 to the H1R, stably expressed on adherent cells, was measured in 
the presence of various concentrations mepyramine (a) doxepin (b) or levocetirizine (c). AV082 binding was 
measured continuously by NanoBRET for 60 min. The kinetic binding of Gmep to the H1R, stably expressed 
on freshly thawed cells in suspension, was measured in the presence of various concentrations mepyramine 
(d) doxepin (e) or levocetirizine (f). Gmep binding was measured continuously by HTRF for 180 min. 
Representative graphs are shown of ≥3 experiments (a–f).
Figure 8. Comparison of the binding properties of unlabeled ligands as measured by using orthogonal assays 
at 25 °C. The binding rate constants of unlabeled ligands that were determined using the fluorescent probes 
AV082 and Gmep were compared with the binding constants obtained with [3H]mepyramine. A comparison of 
the pKi values (a) (from equilibrium competition binding experiments) is depicted as well as the comparison of 
kon (b) and koff (c) values (from kinetic competition association experiments). Dashes lines represent a perfect 
correlation respective to the X-axis values and solid lines represent the linear regression lines.
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logkoff values determined with Gmep as probe (HTRF assay) also correlated with those determined using [3H]
mepyramine as probe (Fig. 8c; R2 = 0.96, P < 0.0001). However, when employing AV082 (NanoBRET assay) in 
competitive association experiments, the relative differences in the koff values between the unlabeled ligands differ 
from those observed in the orthogonal assays (Fig. 8c). Since both the Ki-values and kon values correlate between 
orthogonal assays, the koff can be calculated (Ki × kon) for the NanoBRET assay in order to estimate the relative 
differences in the koff between unlabeled ligands. As expected, these calculated values correlate better with the 
observed values in the orthogonal assays (Supplementary Fig. 4).
Discussion
In GPCR drug discovery, drug-receptor binding kinetics are often quantified using competition association 
experiments with a radioligand probe. Despite the increased use of this methodology, it is unclear whether the 
kinetic properties of the probe influence the obtained kinetic binding parameters of unlabeled ligands. Therefore, 
in this study we employed two radioligand probes, that differ in their H1R binding kinetics ([3H]mepyramine 
and [3H]levocetirizine), to measure the binding rate constants of a diverse set of unlabeled antagonists. The 
analysis shows that the kon and koff values obtained with each probe correlate between both probe-specific data-
sets (Fig. 5a,b). However, large differences in the binding rate constants are observed for some compounds, e.g., 
VUF14454 and VUF14544. Moreover, although more than 10-fold differences in the koff are observed among 
(S)-cetirizine, triprolidine, mepyramine, VUF14454, VUF14493 and VUF14544 when using [3H]mepyramine 
as probe, no difference is observed when the koff are measured for the same set of unlabeled ligands with [3H]
levocetirizine as probe. The comparison of these two datasets therefore suggests a probe-dependent limit to dis-
criminate binding rate constants of unlabeled ligands. A related probe-dependent effect is apparent in the relative 
errors of the determined kon (Fig. 6a) and koff values (Fig. 6b) of the unlabeled ligands. In our competitive binding 
experiments, only the binding of the probe can be directly observed. When unlabeled ligands reach a binding 
equilibrium rapidly, before noticeable binding of the probe, binding kinetics of these unlabeled ligands is masked 
by the slow onset of probe binding at each time point. Since the onset of a receptor-binding equilibrium is faster 
with increasing koff of the respective ligands19, it seems logical that at some point, when the unlabeled ligands have 
an increasingly high koff compared to that of the probe, kinetic binding of the unlabeled ligands can no longer 
be distinguished. This is in line with the observation that the relative error in the fitted binding rate constants 
increases when the corresponding mean koff value (i.e. from the same competitive association curve) increases 
(Fig. 6). Moreover, a pronounced increase in the relative error is observed when the unlabeled ligands dissociate 
faster than the respective radioligand (koff unlabeled > koff radioligand, see arrows Fig. 6a,b). This implies that [3H]
mepyramine, which has a 100-fold higher koff than [3H]levocetirizine, is better suited to discriminate the binding 
kinetics of fast dissociating (high koff) unlabeled ligands at the H1R. Moreover, in our dataset the kon (Fig. 7a) and 
koff (Fig. 7b) are fitted with a higher accuracy using [3H]mepyramine as probe for unlabeled ligands with a resi-
dence time less than 100 min (log koff > −2).
In contrast to the determined kon-values, which show a growing inaccuracy upon increases of the linked 
koff-value (Fig. 6a), the koff-values are increasingly inaccurate at the lower end of the spectrum as well, i.e. both 
with low koff as well as high koff values (Fig. 6b). Interestingly, a probe dependent difference in inaccuracy in these 
determinations is again apparent. However, for slowly binding unlabeled ligands (residence time of more than 
100 min; fitted log koff < −2) a moderately better accuracy is obtained when using [3H]levocetirizine (and not 
[3H]mepyramine) as probe in competition association experiments (Fig. 6b).
Taken together, analysis of the competitive association radioligand binding data show probe-dependent dif-
ferences in the measured binding rate constants of unlabeled ligands, which result (at least to some extent) from 
the accuracy with which these binding rate constants can be fitted to the competitive association curves of the 
radioligand probes. Considering that the accuracy of the measured binding rate constants decreased most exten-
sively for unlabeled ligands that bind the receptor faster than the probe (koff unlabeled > koff radioligand), it is 
recommended to use a fast binding probe for the GPCR of interest (like [3H]mepyramine for the H1R).
To avoid that the kinetics of the probe will mask the binding kinetics of the unlabeled ligands, the koff of the 
probe should ideally be higher than that of the unlabeled ligands. In radioligand binding experiments, the bound 
radioligand should not dissociate during the wash steps. A minimum residence time is therefore required and 
the koff should probably not go beyond 1 min−1 (at room temperature). For probes in fluorescent binding experi-
ments, which do not require wash steps, probes could be designed to have a very high koff. There are not yet suffi-
cient structure-kinetics-relationships available that allow clear cut optimization of the koff. However, reducing the 
binding affinity sufficiently will in most cases increase the koff35. Introducing subtle steric clashes in the binding 
pocket22 might therefore be a way to fine-tune the koff of fluorescent probes.
Comparing the binding kinetics of unlabeled H1R antagonists determined in experiments using the fluo-
rescently labelled H1R probes AV082 and Gmep with those obtained using [3H]mepyramine, again reveals that 
the determined pKi values and the binding rate constants are highly correlated (Fig. 8). This might be explained 
(partially) by the fact that all three H1R probes have quite similar koff values (Table 1). In fact, the correlations 
for the measured binding rate constants were stronger when comparing the different assays (Fig. 8a,b) than 
when comparing the datasets obtained with the different radioligands (Fig. 6a,b). The notable exception were 
the koff-values determined with AV082 competition association binding experiments (measured by NanoBRET), 
which deviated only slightly among unlabeled ligands, suggesting again a probe-dependent limitation for dis-
criminating the binding kinetics of unlabeled ligands. However, this effect is most likely not explained by the 
binding kinetics of the H1R probe as the binding rate constants of AV082 and [3H]mepyramine differed only 
<3-fold. Assay-dependent differences might therefore also underlie the observed disconnect between koff val-
ues. It has been described that the measurement of drug-target binding kinetics can be additionally convoluted in 
pharmacological assays by rebinding36,37, the mechanism of ligand binding38,39, and the differences in local ligand 
concentration40, all of which cannot be accounted for during this analysis. Interestingly, in silico docking suggests 
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that the hydrophobic fluorophore of large fluorescent ligands, like AV082, can protrude out of the GPCR 7TM 
pocket and might incorporate in the membrane29, which is distinct from the binding mode of [3H]mepyramine, 
which is deeply buried within the transmembrane region of the H1R41–43. One can speculate that the simple 
one-step binding mechanism that is the conceptual basis of the Motulsky-Mahan model for probe binding to the 
H1R, is not a valid approximation in the case of AV082. Besides the probe, the extracellular N-terminal tag of the 
employed H1R was different between the NanoBRET-based detection of AV082 binding and the HTRF-based 
detection of Gmep binding to the H1R protein. Moreover, since AV082 was the only probe that was employed in 
binding experiments on adherent living cells, the extracellular environment might shape a unique exosite that 
promotes ligand-rebinding. For example, the epithelial layer of human lungs in organ bath perfusion experiments 
proved crucial for the insurmountable antagonism of the H1R imposed by azelastine44. Since the insurmountable 
antagonism depends on the length of the receptor-occupancy by azelastine23,44,45, the extracellular environment 
may in some cases contribute to the observed ligand binding kinetics.
In conclusion, the Motulsky-Mahan approach is a useful approach to quantify the binding rate constants of 
unlabeled GPCR ligands, especially with the high throughput and kinetic resolution that can be obtained with 
fluorescent ligand binding experiments. However, it should be taken into account that probe-dependent and 
assay-dependent factors can have an impact on the measured binding kinetics of the unlabeled ligands. It is rec-
ommended to use orthogonal approaches to confirm the binding kinetics of a set of reference compounds, for 
example, by studying the kinetics by which ligands functionally modulate GPCR activity. Previously, we found 
the ligand binding kinetics at the H1R of a set of H1R antagonists to correlate well with their kinetic effects on 
functional H1R responses23,31. Furthermore, the use of benchmark ligands will also allow comparison between 
different methodologies and will allow the selection of the best method to reach highest confidence for discrim-
inating the target-binding kinetics of unlabeled ligands by the Motulsky-Mahan method. Considering that the 
Motulsky-Mahan model is by far the most frequently used way to derive the residence time of GPCR ligands, this 
study provides important considerations for the study of drug-target binding kinetics at GPCRs.
Data Availability
The datasets generated and analyzed during the current study are available from the corresponding author on 
reasonable request.
References
 1. Swinney, D. C. Biochemical mechanisms of drug action: what does it take for success? Nat. Rev. Drug Discov. 3, 801–8 (2004).
 2. Swinney, D. C. Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001–2004: 
mechanisms leading to optimal efficacy and safety. Curr Top Med Chem 6, 461–78 (2006).
 3. Copeland, R. A., Pompliano, D. L. & Meek, T. D. Drug-target residence time and its implications for lead optimization. Nat. Rev. 
Drug Discov. 5, 730–9 (2006).
 4. Cumming, J. G. et al. Potential strategies for increasing drug-discovery productivity. Future Med. Chem. 6, 515–27 (2014).
 5. Hoffmann, C. et al. Ligand Residence Time at G-protein-Coupled Receptors–Why We Should Take Our Time To Study It. Mol. 
Pharmacol. 88, 552–60 (2015).
 6. Swinney, D. C. Applications of Binding Kinetics to Drug Discovery. Pharmaceut. Med. 22, 23–34 (2008).
 7. Copeland, R. A. The drug–target residence time model: a 10-year retrospective. Nat. Rev. Drug Discov. 15, 1–9 (2015).
 8. Lu, H. & Tonge, P. J. Drug-target residence time: critical information for lead optimization. Curr. Opin. Chem. Biol. 14, 467–74 
(2010).
 9. Guo, D., Hillger, J. M., IJzerman, A. P. & Heitman, L. H. Drug-Target Residence Time-A Case for G Protein-Coupled Receptors. 
Med. Res. Rev. 34, 856–92 (2014).
 10. Unett, D., Gatlin, J. & Anthony, T. Kinetics of 5-HT2B receptor signaling: Profound agonist-dependent effects on signaling onset and 
duration. Pharmacol. 645–659 (2013).
 11. Guo, D. et al. Dual-point competition association assay: a fast and high-throughput kinetic screening method for assessing ligand-
receptor binding kinetics. J. Biomol. Screen. 18, 309–20 (2013).
 12. Ramsey, S. J., Attkins, N. J., Fish, R. & van der Graaf, P. H. Quantitative pharmacological analysis of antagonist binding kinetics at 
CRF1 receptors in vitro and in vivo. Br. J. Pharmacol. 164, 992–1007 (2011).
 13. Gillard, M., Van Der Perren, C., Moguilevsky, N., Massingham, R. & Chatelain, P. Binding characteristics of cetirizine and 
levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194). Mol. Pharmacol. 61, 391–9 (2002).
 14. Dowling, M. R. & Charlton, S. J. Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 
receptor. Br. J. Pharmacol. 148, 927–37 (2006).
 15. Sullivan, S. K. et al. Kinetics of nonpeptide antagonist binding to the human gonadotropin-releasing hormone receptor: Implications 
for structure-activity relationships and insurmountable antagonism. Biochem. Pharmacol. 72, 838–49 (2006).
 16. Cassel, J. A., Daubert, J. D. & DeHaven, R. N. [(3)H]Alvimopan binding to the micro opioid receptor: comparative binding kinetics 
of opioid antagonists. Eur. J. Pharmacol. 520, 29–36 (2005).
 17. Hoare, S. R. & Usdin, T. B. Tuberoinfundibular peptide (7-39) [TIP(7-39)], a novel, selective, high-affinity antagonist for the 
parathyroid hormone-1 receptor with no detectable agonist activity. J. Pharmacol. Exp. Ther. 295, 761–70 (2000).
 18. Bosma, R., Mocking, T. A. M., Leurs, R. & Vischer, H. F. In Histamine Receptors as Drug Targets (eds Tiligada, E. & Ennis, M.) 
115–55, 10.1007/978-1-4939-6843-5_5 (Springer New York, 2017).
 19. Motulsky, H. & Mahan, L. The kinetics of competitive radioligand binding predicted by the law of mass action. Mol. Pharmacol. 25, 
1–9 (1984).
 20. Simons, F. E. R. & Simons, K. J. Histamine and H1-antihistamines: celebrating a century of progress. J. Allergy Clin. Immunol. 128, 
1139–50 (2011).
 21. Gillard, M. & Chatelain, P. Changes in pH differently affect the binding properties of histamine H1 receptor antagonists. Eur. J. 
Pharmacol. 530, 205–14 (2006).
 22. Kuhne, S. et al. Identification of Ligand Binding Hot Spots of the Histamine H1 Receptor following Structure-Based Fragment 
Optimization. J. Med. Chem. 59, 9047–61, https://doi.org/10.1021/acs.jmedchem.6b00981 (2016).
 23. Bosma, R. et al. The target residence time of antihistamines determines their antagonism of the G protein-coupled histamine H1 
receptor. Front. Pharmacol. 8, 667–667 (2017).
 24. Wittmann, H.-J., Seifert, R. & Strasser, A. Influence of the N-terminus and the E2-loop onto the binding kinetics of the antagonist 
mepyramine and the partial agonist phenoprodifen to H(1)R. Biochem. Pharmacol. 82, 1910–8 (2011).
13Scientific RepoRts |          (2019) 9:7906  | https://doi.org/10.1038/s41598-019-44025-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
 25. Panula, P. et al. International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors. Pharmacol. Rev. 67, 601–55 
(2015).
 26. Hill, S. J., Emson, P. C. & Young, J. M. The binding of [3H]mepyramine to histamine H1 receptors in guinea-pig brain. J. Neurochem. 
31, 997–1004 (1978).
 27. Kanba, S. & Richelson, E. Histamine H1 receptors in human brain labelled with [3H]doxepin. Brain Res. 304, 1–7 (1984).
 28. Schuetz, D. A. et al. Kinetics for Drug Discovery: an industry-driven effort to target drug residence time. Drug Discov. Today 22, 
896–911 (2017).
 29. Stoddart, L. A. et al. Development of novel fluorescent histamine H1-receptor antagonists to study ligand-binding kinetics in living 
cells. Sci. Rep. 8, 1572 (2018).
 30. Schiele, F., Ayaz, P. & Fernández-Montalván, A. A universal homogeneous assay for high-throughput determination of binding 
kinetics. Anal. Biochem. 468, 42–49 (2015).
 31. Bosma, R., Moritani, R., Leurs, R. & Vischer, H. F. BRET-based β-arrestin2 recruitment to the histamine H1 receptor for 
investigating antihistamine binding kinetics. Pharmacol. Res. 111, 679–87 (2016).
 32. Nederpelt, I. et al. Characterization of 12 GnRH peptide agonists - A kinetic perspective. Br. J. Pharmacol. 173, 128–41 (2016).
 33. Nonaka, H. et al. Unique binding pocket for KW-4679 in the histamine H1 receptor. Eur. J. Pharmacol. 345, 111–7 (1998).
 34. Cheng, Y. & Prusoff, W. H. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per 
cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099–108 (1973).
 35. Pan, A. C., Borhani, D. W., Dror, R. O. & Shaw, D. E. Molecular determinants of drug-receptor binding kinetics. Drug Discov Today 
18, 667–673 (2013).
 36. Vauquelin, G. & Charlton, S. J. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br. J. 
Pharmacol. 161, 488–508 (2010).
 37. Vauquelin, G. & Van Liefde, I. Radioligand dissociation measurements: potential interference of rebinding and allosteric 
mechanisms and physiological relevance of the biological model systems. Expert Opin. Drug Discov. 7, 583–95 (2012).
 38. Swinney, D. C. et al. A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor 
small molecule allosteric ligands. Br. J. Pharmacol. 171, 3364–75 (2014).
 39. Vauquelin, G., Van Liefde, I. & Swinney, D. C. On the different experimental manifestations of two-state ‘induced-fit’ binding of 
drugs to their cellular targets. Br. J. Pharmacol. 173, 1268–85 (2016).
 40. Sykes, D. A. et al. Observed drug-receptor association rates are governed by membrane affinity: the importance of establishing 
‘micro-pharmacokinetic/pharmacodynamic relationships’ at the β2-adrenoceptor. Mol. Pharmacol. 85, 608–17 (2014).
 41. Mocking, T. et al. In Histamine Receptors (eds Blandina, P. & Passani, M. B.) 1–49, https://doi.org/10.1007/978-3-319-40308-3 
(Humana Press, Cham, 2016).
 42. Shimamura, T. et al. Structure of the human histamine H1 receptor complex with doxepin. Nature 475, 65–70 (2011).
 43. Kooistra, A. J., Kuhne, S., de Esch, I. J. P., Leurs, R. & de Graaf, C. A structural chemogenomics analysis of aminergic GPCRs: lessons 
for histamine receptor ligand design. Br. J. Pharmacol. 170, 101–26 (2013).
 44. Slack, R. J., Hart, A. D., Luttmann, M. A., Clark, K. L. & Begg, M. In vitro characterisation of the duration of action of the histamine-1 
receptor antagonist azelastine. Eur. J. Pharmacol. 670, 586–92 (2011).
 45. Kenakin, T., Jenkinson, S. & Watson, C. Determining the potency and molecular mechanism of action of insurmountable 
antagonists. J. Pharmacol. Exp. Ther. 319, 710–723 (2006).
Acknowledgements
This research was financially supported by the EU/EFPIA Innovative Medicines Initiative (IMI) Joint 
Undertaking, K4DD (Grant No. 115366).
Author Contributions
R.B., L.I., H.V. and R.L. contributed the data and analysis for the “radioligand binding assays” methodology. L.S., 
M.B., S.B. and S.H. contributed the data and analysis for the “NanoBRET binding assays” methodology. V.G. and 
A.F. contributed the data and analysis for the “HTRF binding assays” methodology. Nick Bushby contributed to 
the synthetic procedures. All authors participated in writing of the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-44025-5.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
